Wednesday, July 14, AstraZeneca (AZ) announced that the UK’s Competition and Markets Authority (CMA) has cleared the Alexion buyout without raising any antitrust concerns.
The go-ahead follows blessings from competition authorities in the US and EU and marks the final regulatory approval the company needs to seal the deal, which is now expected to close July 21.
The transaction, unveiled in December, gives AZ additional know-how in immunology and a presence in rare diseases.
The combination of Alexion offers an immediate boost to AZ’s top line thanks mainly to complement inhibitors Soliris and Ultomiris, which together brought in US$1.37 billion in first-quarter sales. AZ also sees broad application of Alexion’s complement platform and other immunology technologies in various therapeutic areas—including oncology—to fuel future growth.
Once the takeover completes, AZ is creating a rare disease unit bearing Alexion’s name with headquarters at the US firm’s current location in Boston. The franchise will be led by Marc Dunoyer, currently AZ’s chief financial officer, who will also take on the title of chief strategy officer. His CFO role will be filled by Alexion’s CFO, Aradhana Sarin.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI